接受阿帕他胺治疗的转移性去势敏感性前列腺癌患者中出现影像学进展而无对应前列腺特异性抗原进展:TITAN试验的二次分析
该研究基于TITAN试验个体数据,分析326例发生影像学进展的转移性去势敏感性前列腺癌患者。阿帕他胺组不一致进展(无同步或前置PSA进展的影像学进展)发生率为52.2%(60/115),安慰剂组为27.5%(58/211),差异有统计学意义(p < 0.001)。多变量logistic回归显示不一致进展与阿帕他胺治疗相关,且与更短的影像学无进展生存期相关。
要点
- 阿帕他胺组不一致进展发生率52.2%(60/115),安慰剂组27.5%(58/211),p < 0.001。
- 多变量logistic回归显示不一致进展与阿帕他胺治疗相关。
- 不一致进展与更短的影像学无进展生存期相关。
核心结论
- 在接受阿帕他胺治疗的转移性去势敏感性前列腺癌患者中,近半数发生影像学进展者并无对应的PSA进展,提示在此情境下过度依赖PSA监测可能不足以评估疾病活动。
研究设计与样本
- TITAN试验的二次分析,分析随访期间发生影像学进展的随机化患者个体数据(N = 326)。
主要发现
- 发生影像学进展的患者中,阿帕他胺组115例(35.3%),安慰剂组211例(64.7%)。
- 不一致进展(无同步或前置PSA进展的影像学进展,依据PCWG2定义)在阿帕他胺组为52.2%(60/115),在安慰剂组为27.5%(58/211),p < 0.001。
- 多变量logistic回归分析显示不一致进展与阿帕他胺治疗相关。
- 研究发现不一致进展与更短的影像学无进展生存期相关的证据。
临床怎么用
- 作者认为,在接受阿帕他胺治疗的转移性去势敏感性前列腺癌患者中,即使PSA检测显示无变化,影像学也可能显示癌症进展;这凸显了在使用阿帕他胺管理mCSPC时定期影像学检查的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: In prostate cancer treated with androgen deprivation therapy (ADT), the initial sign of treatment resistance is often prostate-specific antigen (PSA) progression, followed by radiographic progression. However, the association between these two forms of progression remains unclear, especially in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with androgen receptor pathway inhibitors. We sought to evaluate the association between radiographic progression, PSA progression, and outcomes of apalutamide therapy in mCSPC. METHODS: We analyzed individual participant-level data for patients randomized within the TITAN trial who experienced radiographic progression during follow-up (N = 326). This study investigated radiographic progression without simultaneous or preceding PSA progression, as defined by the Prostate Cancer Working Group 2 (discordant progression), and explored the association of such progression with radiographic progression-free survival. KEY FINDINGS AND LIMITATIONS: Among the patients who developed radiographic progression, 115 (35.3%) had been treated with apalutamide plus ADT (the apalutamide group) and 211 (64.7%) with placebo plus ADT (the placebo group). Discordant progression occurred in 52.2% of patients (60 of 115) in the apalutamide group and 27.5% (58 of 211) in the placebo group (p < 0.001). A multivariable logistic regression analysis showed that discordant progression was associated with apalutamide treatment. We found evidence of an association between discordant progression and shorter radiographic progression-free survival. CONCLUSIONS AND CLINICAL IMPLICATIONS: This study found that nearly half of the patients with mCSPC treated with apalutamide who experienced radiographic progression developed it without corresponding PSA progression, suggesting that heavy reliance on PSA monitoring may be inadequate for assessing disease activity in this context. PATIENT SUMMARY: In patients who have metastatic castration-sensitive prostate cancer (mCSPC) and are being treated with apalutamide, radiographic images may show cancer progression even if prostate-specific antigen tests indicate no change. This highlights the importance of regular imaging when using apalutamide to manage mCSPC.
引用
- Fukuokaya W, Yanagisawa T, Mori K, et al. Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial. Eur Urol Oncol. 2024. PMID: 38688767. doi:10.1016/j.euo.2024.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。